Inventor
DRANOFF GLENN
US33 patents
⚠️ This page may combine multiple inventors who share the name “DRANOFF GLENN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
DANA FARBER CANCER INST INC
13 patentsUS10876120B2Dec 29, 2020
Methods and compositions for reducing immunosupression by tumor cells
DANA FARBER CANCER INST INC5 citations81
US9944931B2Apr 17, 2018
Methods and compositions for reducing immunosupression by tumor cells
DANA FARBER CANCER INST INC11 citations81
US9402905B2Aug 2, 2016
Therapeutic peptides
DANA FARBER CANCER INST INC14 citations81
US7419958B2Sep 2, 2008
Method of attenuating reactions to skin irritants
DANA FARBER CANCER INST INC13 citations79
US7250291B1Jul 31, 2007
Tumor antigens and uses thereof
DANA FARBER CANCER INST INC14 citations77
US11597934B2Mar 7, 2023
Methods and compositions for reducing immunosuppression by tumor cells
DANA FARBER CANCER INST INC3 citations70
US10793633B2Oct 6, 2020
Therapeutic peptides
DANA FARBER CANCER INST INC2 citations70
US10106611B2Oct 23, 2018
Antibodies that bind to MHC class I polypeptide-related sequence A
DANA FARBER CANCER INST INC5 citations70
US10279021B2May 7, 2019
Vaccine compositions and methods for restoring NKG2D pathway function against cancers
DANA FARBER CANCER INST INC1 citations61
US11851472B2Dec 26, 2023
NKG2D-IG fusion protein for cancer immunotherapy
DANA FARBER CANCER INST INC1 citations59
US10865232B2Dec 15, 2020
NKG2D-IG fusion protein for cancer immunotherapy
DANA FARBER CANCER INST INC1 citations59
US11624093B2Apr 11, 2023
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
DANA FARBER CANCER INST INC0 citations55
US10226476B2Mar 12, 2019
Method of attenuating reactions to skin irritants
DANA FARBER CANCER INST INC0 citations47
NOVARTIS AG
7 patentsUS9988452B2Jun 5, 2018
Antibody molecules to PD-L1 and uses thereof
NOVARTIS AG30 citations93
US10851165B2Dec 1, 2020
Antibody molecules to PD-L1 and methods of treating cancer
NOVARTIS AG10 citations83
US10662247B2May 26, 2020
Compositions and methods of use for augmented immune response and cancer therapy
NOVARTIS AG2 citations70
US11382905B2Jul 12, 2022
Immunomodulation by IAP inhibitors
NOVARTIS AG1 citations69
US12037583B2Jul 16, 2024
Compositions and methods for immunooncology
NOVARTIS AG2 citations67
US10786491B2Sep 29, 2020
Immunomodulation by IAP inhibitors
NOVARTIS AG1 citations58
US12383601B2Aug 12, 2025
Chimeric antigen receptors and uses thereof
NOVARTIS AG1 citations57
HARVARD COLLEGE
6 patentsUS9821045B2Nov 21, 2017
Controlled delivery of TLR3 agonists in structural polymeric devices
HARVARD COLLEGE25 citations94
US9370558B2Jun 21, 2016
Controlled delivery of TLR agonists in structural polymeric devices
HARVARD COLLEGE32 citations94
US10682400B2Jun 16, 2020
Combination vaccine devices and methods of killing cancer cells
HARVARD COLLEGE11 citations86
US10568949B2Feb 25, 2020
Method of eliciting an anti-tumor immune response with controlled delivery of TLR agonists in porous polymerlc devices
HARVARD COLLEGE10 citations84
US10258677B2Apr 16, 2019
Continuous cell programming devices
HARVARD COLLEGE8 citations84
US11998593B2Jun 4, 2024
Combination vaccine devices and methods of killing cancer cells
HARVARD COLLEGE0 citations62